Investing.com - Avadel Pharma reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Avadel Pharma announced earnings per share of $-0.38 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.3867 on revenue of $0.00.
Avadel Pharma shares are up 64.97% from the beginning of the year, still down 3.76% from its 52 week high of $11.45 set on November 8. They are outperforming the Nasdaq which is up 24.13% from the start of the year.
Avadel Pharma shares gained 5.76% in intra-day trade following the report.
Avadel Pharma follows other major Healthcare sector earnings this month
Avadel Pharma's report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Pfizer had beat expectations on November 2 with third quarter EPS of $1.34 on revenue of $24.09B, compared to forecast for EPS of $1.08 on revenue of $22.58B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar